Pay in 4 interest-free payments of $6.87 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
& Newgard, C
Retatrutide remains investigational and has not been approved by the FDA for routine prescribing
However, fibromyalgia is a real condition that causes real pain and has a real impact on your life
Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial In TRIUMPH-1, participants on 12 mg retatrutide lost an average of 70.3 lbs (28.3%) over 80 weeks with 45.3% of participants achieving 30% weight loss, a level long associated with bariatric surgery Individuals with a baseline BMI 35 who participated in a study extension continued to lose weight, and achieved up to an average of 85.0 lbs (30.3%) weight loss at 104 weeks At the 4 mg dose, reached with only a single escalation step, participants lost an average of 47.2 lbs (19.0%) at 80 weeks with a lower observed discontinuation rate due to adverse events vs
No cardiovascul
US$ 21.78
US$ 24.77
US$ 23.39
